Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/103836OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/119515 Applicant SHANGHAI PHARMAEXPLORER CO., LTD. Inventor CHAI, Xiaojuan
Provided are a murine or human-mouse chimeric antibody targeting OX40 and a preparation method therefor, wherein the antibody binds to the OX40 antigen and has an anti-tumor activity and other activities.
2.WO/2020/104496BISPECIFIC ANTIBODY TARGETING TRANSFERRIN RECEPTOR 1 AND SOLUBLE ANTIGEN
WO 28.05.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/EP2019/081873 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor POUL, Marie-Alix
The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of the bispecific antibody with TfR1 increases its persistence in vivo through an FcRn-like mechanism. It has been demonstrated on MCF7 cell line that the bispecific antibody induces soluble antigen (IL6) uptake through TfR1 mediated endocytosis. Effects of the bispecific antibody on XG6 cell lines viability have been demonstrated, notably on iron and IL-6 deprivation. Hence, the inventors design an improved sweeping antibody which can specifically target tumors and inflammatory cells expressing TfR1. By its unique mode of interaction with TfR1, its ability to induce soluble uptake antigen through TfR1 mediated endocytosis and its capacity to deprive cells of iron, known for being required in tumors growth and progression and development of inflammatory pathologies, the bispecific antibody can be used in the treatment of cancer and inflammatory pathologies.
3.WO/2020/106116DOSING REGIMEN FOR TREATING INFLUENZA VIRUS DISEASES
WO 28.05.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/KR2019/016194 Applicant CELLTRION, INC. Inventor KIM, Sung Hyun
The present invention pertains to a dosing regimen for treating influenza virus diseases, and more specifically, to a method for treating influenza virus-related diseases through the administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. The treatment method according to the present invention enables influenza A virus-related diseases to be treated through the intravenous administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. In addition, the treatment method according to the present invention can satisfy unmet medical needs for biological therapeutic agents for influenza virus-related diseases.
4.WO/2020/102895METHODS OF TREATING AN AUTOIMMUNE DISEASE
WO 28.05.2020
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/CA2019/051653 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor GOMMERMAN, Jennifer
The present disclosure provides methods of treating an autoimmune disease (e.g., multiple sclerosis) or reducing inflammation by administering at least a B-cell activating Factor (BAFF) polypeptide to a subject in need thereof. The effect of BAFF on plasmablast/plasma cells and their role in autoimmune diseases is also disclosed.
5.WO/2020/102935ANTI-IL-25 ANTIBODIES AND USE THEREOF
WO 28.05.2020
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/CN2018/116170 Applicant SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD. Inventor GUO, Li
The present invention provides anti-IL-25 antibodies that are directed against (human) IL-25, nucleic acids that encode such antibodies, compositions, and in particular pharmaceutical compositions that comprise such antibodies; and uses of such antibodies and compositions.
6.WO/2020/103885ANTI-PD-1 ANTIBODIES AND USES THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/119798 Applicant BEIJING BIOCYTOGEN CO., LTD Inventor YANG, Yi
Provided are anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen -binding fragments, and the uses thereof.
7.WO/2020/106695METHODS OF TREATING CANCER
WO 28.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2019/062166 Applicant ARIAGEN, INC. Inventor COLABUONO, Peter
The present disclosure relates to methods of treating cancer in a patient using a combination of an inhibitor of an immune checkpoint protein and an indole compound or its phosphate derivative.
8.WO/2020/106975MANUFACTURE OF VIRUS
WO 28.05.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2019/062643 Applicant WESTERN ONCOLYTICS LTD. Inventor WRIGHT, Paul Andrew
Provided herein are methods of manufacturing viruses. Also provided herein are bioreactors comprising virus-infected host cells comprising viruses. In some aspects, the present disclosure relates to production of recombinant oncolytic viruses, e.g., recombinant vaccinia viruses.
9.WO/2020/102904PCDH1-BINDING AGENTS AND USES THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CA2019/051669 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor MOFFAT, Jason
The disclosure is directed to novel PCDH-1-binding agents, and to methods and uses of these binding agents. In one embodiment, the disclosure provides antibody variable regions which specifically bind the EC1 domain of PDCH1. The disclosure is also directed to uses of the novel PCDH1-binding agents for treating or preventing infection with New-World hantavirus.
10.WO/2020/104694VSV CHIMERIC VECTORS
WO 28.05.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2019/082328 Applicant VIRA THERAPEUTICS GMBH Inventor NOLDEN, Tobias
The present invention relates to VSV chimeric vectors, characterized in that the vectors comprise a gene coding for a glycoprotein GP of the Dandenong virus (DANDV) or Mopeia virus (MOPV) and lack a functional gene coding for envelope protein G of the VSV. The invention also provides VSV chimeric vector systems. In addition, the invention relates to uses of the VSV chimeric vectors and systems of the invention, including the use in medicine such as in the treatment of solid tumors.